Zydus Lifesciences' Saroglitazar shows higher MASH resolution rates than placebo in phase 2b trial
Zydus Therapeutics reported that its investigational drug saroglitazar achieved resolution of steatohepatitis without worsening of fibrosis in 39.1% of patients receiving the 4 mg dose and 32.4% receiving 2 mg,…
Zydus Lifesciences+1.28%
